Popovits Kimberly J 4

What Happened

• Kimberly J. Popovits, a director of 10x Genomics, received an award of 8,829 restricted stock units (RSUs) on June 4, 2026. The grant is reported as an acquisition (code A) at $0.00 per unit — the Form 4 lists $0 cash paid for the award. This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-04 (reported on Form 4 filed 2026-06-08).
• Transaction type/code: Award/Grant (A).
• Units granted: 8,829 RSUs; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting/footnote: RSUs are contingent rights to receive one share upon vesting. 1/4 of the RSUs vest on each quarterly anniversary measured from May 21, 2026, subject to continued service through each vesting date.
• Filing timeliness: Filed June 8, 2026 — within the standard two-business-day reporting window for Form 4 filings.
• Exhibit: Exhibit 24.1 (Power of Attorney) attached.

Context

• RSUs are a form of equity compensation: they do not convert to actual shares until they vest, and they generally reflect compensation for service rather than an immediate market view. Grants to company directors are common and should be interpreted as part of pay and retention programs rather than direct insider buying or selling.